NO931631D0 - Kompleksdannende midler og maalsoeking av radioaktive immunoreagenser nyttige innen terapeutiske og diagnostiske bildedannende sammensetninger og fremgangsmetoder - Google Patents

Kompleksdannende midler og maalsoeking av radioaktive immunoreagenser nyttige innen terapeutiske og diagnostiske bildedannende sammensetninger og fremgangsmetoder

Info

Publication number
NO931631D0
NO931631D0 NO931631A NO931631A NO931631D0 NO 931631 D0 NO931631 D0 NO 931631D0 NO 931631 A NO931631 A NO 931631A NO 931631 A NO931631 A NO 931631A NO 931631 D0 NO931631 D0 NO 931631D0
Authority
NO
Norway
Prior art keywords
targeting
immunore
radioactive
therapeutic
agents
Prior art date
Application number
NO931631A
Other languages
English (en)
Other versions
NO931631L (no
Inventor
John L Toner
David A Hilborn
Bruce J Murray
Timothy Z Hossain
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of NO931631D0 publication Critical patent/NO931631D0/no
Publication of NO931631L publication Critical patent/NO931631L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
NO93931631A 1990-11-08 1993-05-05 Kompleksdannende midler og maalsoeking av radioaktive immunoreagenser nyttige innen terapeutiske og diagnostiske bildedannende sammensetninger og fremgangsmetoder NO931631L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61086190A 1990-11-08 1990-11-08
US07/784,333 US5367080A (en) 1990-11-08 1991-10-29 Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
PCT/US1991/008253 WO1992008494A2 (en) 1990-11-08 1991-11-07 Targeting radioactive immunoreagents

Publications (2)

Publication Number Publication Date
NO931631D0 true NO931631D0 (no) 1993-05-05
NO931631L NO931631L (no) 1993-06-23

Family

ID=27086372

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931631A NO931631L (no) 1990-11-08 1993-05-05 Kompleksdannende midler og maalsoeking av radioaktive immunoreagenser nyttige innen terapeutiske og diagnostiske bildedannende sammensetninger og fremgangsmetoder

Country Status (21)

Country Link
US (4) US5367080A (no)
EP (1) EP0624097B1 (no)
JP (1) JP3292301B2 (no)
KR (1) KR930701974A (no)
AT (1) ATE164082T1 (no)
AU (2) AU667030B2 (no)
BR (1) BR9107074A (no)
CA (1) CA2095123A1 (no)
DE (1) DE69129127T2 (no)
DK (1) DK0624097T3 (no)
ES (1) ES2113892T3 (no)
FI (1) FI932083A (no)
GR (1) GR3026713T3 (no)
HU (1) HUT67298A (no)
IE (1) IE913907A1 (no)
MX (1) MX9101999A (no)
NO (1) NO931631L (no)
NZ (1) NZ240521A (no)
PT (1) PT99460B (no)
TW (1) TW201271B (no)
WO (1) WO1992008494A2 (no)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
ATE203168T1 (de) * 1992-05-07 2001-08-15 Nycomed Imaging As Komplexbildnermittel und zielimmunoreagenzien
ES2105332T3 (es) * 1992-10-14 1997-10-16 Nycomed Imaging As Polimeros quelantes.
CA2152777A1 (en) * 1992-12-28 1994-07-07 Hirofusa Shirai Pharmaceutical use of terpyridine derivatives
US5760191A (en) * 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
WO1994020523A1 (en) * 1993-03-10 1994-09-15 The Wellcome Foundation Limited Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
US5744119A (en) * 1993-05-11 1998-04-28 Sterling Winthrop Preparation of a radioconjugate formulation
US5559214A (en) * 1993-05-28 1996-09-24 Sterling Winthrop Inc. Unsymmetrical complexing agents and targeting immunoreagents useful in thearpeutic and diagnostic compositions and methods
WO1994029333A1 (en) * 1993-06-07 1994-12-22 The Wellcome Foundation Limited Immunoreactive reagents employing monoamine oxidase
DE19505960A1 (de) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
US5562626A (en) * 1995-09-11 1996-10-08 Sanpietro; Joseph A. Safety syringe
AUPO066096A0 (en) * 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
JP4033497B2 (ja) 1996-09-06 2008-01-16 三菱化学株式会社 ワクチン製剤
AU9452198A (en) * 1997-10-15 1999-05-17 Nycomed Imaging As Complexing agents and targeting immunoreagents
AU2530199A (en) * 1998-02-06 1999-08-23 Nycomed Imaging As Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
AU3375599A (en) * 1998-03-31 1999-10-18 Trustees Of Boston University Methods for designing molecular conjugates and compositions thereof
US6314314B1 (en) 1999-01-14 2001-11-06 Seth J. Karp Method for locating an internal bleeding site in a human body
EP1203026A4 (en) * 1999-07-29 2005-03-16 Dyax Corp FRACTIONS BINDING FIBRIN
WO2001077145A2 (en) * 2000-04-12 2001-10-18 Amersham Health As Integrin binding peptide derivatives
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
WO2002031865A1 (en) * 2000-10-13 2002-04-18 Emcore Corporation Method of making an electrode
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
NZ530156A (en) * 2001-07-10 2007-04-27 Ge Healthcare As Peptide-based compounds for targeting integrin receptors for use as diagnostic imaging agents
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
SI2301587T1 (sl) 2002-03-01 2014-11-28 Dyax Corp. KDR in VEGF/KDR vezavni peptidi in njihova uporaba pri diagnozi
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
AU2003274463B2 (en) * 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
ES2692166T3 (es) 2003-03-03 2018-11-30 Dyax Corp. Péptidos que se unen específicamente al receptor de HGF (cMet) y usos de los mismos
WO2005009393A2 (en) * 2003-07-24 2005-02-03 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for preparation
EP2962699A3 (en) 2003-12-01 2016-04-06 Immunomedics Inc. Improved method for preparing conjugates of proteins and chelating agents
AU2004296184B2 (en) * 2003-12-04 2010-12-16 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
CA2561718A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
US20060024229A1 (en) * 2004-07-29 2006-02-02 Seth Karp Method and product for locating an internal bleeding site
US20100034748A1 (en) * 2008-08-07 2010-02-11 Guizhi Li Molecular imaging probes based on loaded reactive nano-scale latex
MX2008002233A (es) * 2005-08-16 2008-03-27 Univ North Carolina At Wilming Ligandos para iones de metal y metodos para elaborar y usar los mismos.
US20090098057A1 (en) * 2007-10-16 2009-04-16 Shiying Zheng Silica-cored carrier particle
AR059193A1 (es) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
US20080167544A1 (en) * 2006-12-01 2008-07-10 Cold Spring Diagnostics, Inc. Compositions And Methods For Locating An Internal Bleeding Site
EP2097438B1 (en) 2006-12-11 2015-08-26 Bracco Imaging S.p.A Fibrin binding peptide conjugates for diagnostic and therapeutic applications
US8906354B2 (en) 2007-02-28 2014-12-09 Bruker Biospin Corporation Loaded latex optical molecular imaging probes containing lipophilic large stokes shift dyes
EP2005970A1 (de) 2007-06-22 2008-12-24 Berlin Science Partners GmbH i.V. Bildgebende Diagnostik durch Kombination von Kontrastmitteln
WO2009082485A1 (en) * 2007-12-26 2009-07-02 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
WO2010107832A1 (en) 2009-03-17 2010-09-23 Bracco Imaging Spa Lhrh-ii peptide analogs
AR075900A1 (es) 2009-03-19 2011-05-04 Wyeth Llc Metodos para la preparacion de acidos (2-(8,9-dioxo-2,6-diazabiciclico (5.2.0) non-1(7)-en-2-il)etil) fosfonico y sus precursores.
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
EP2477986B1 (en) * 2009-09-14 2014-11-12 B.R.A.H.M.S GmbH Phenanthroline derivatives and their use as ligands
FR2969999B1 (fr) * 2011-01-03 2013-02-08 Commissariat Energie Atomique Conjugue, son procede de preparation et ses utilisations
JP2014509585A (ja) * 2011-03-11 2014-04-21 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー フェナントロリン化合物を配位子とする希土類金属錯体
WO2013048832A1 (en) 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
CA2902209A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
WO2015171543A1 (en) 2014-05-05 2015-11-12 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
EP2954934A1 (en) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
CA2949936C (en) 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
CN108290927B (zh) 2015-07-15 2022-06-24 加州理工学院 Il-17f-特异性捕获剂、组合物以及使用和制造的方法
IL260957B2 (en) 2016-02-09 2023-11-01 Bracco Suisse Sa Chimeric, Recombinant Protein Glycoprotein Selectin-P Ligand-1 (PSGL-1) Conjugates, Preparations Containing Them and Uses Thereof
US20170319722A1 (en) 2016-04-04 2017-11-09 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
WO2018085375A1 (en) 2016-11-01 2018-05-11 Ohio State Innovation Foundation Methods for the iodination of biomolecules
US11719705B2 (en) 2017-06-15 2023-08-08 Indi Molecular, Inc. IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
US11638764B2 (en) 2018-11-08 2023-05-02 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US20200291391A1 (en) 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
US20200371101A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
WO2021005131A1 (en) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022123462A1 (en) 2020-12-09 2022-06-16 3B Pharmaceuticals Gmbh Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
JP2024503637A (ja) 2021-01-07 2024-01-26 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4122499A1 (en) 2021-07-23 2023-01-25 3B Pharmaceuticals GmbH Fibroblast activation protein inhibitors and use thereof
WO2023111350A2 (en) 2021-12-17 2023-06-22 3B Pharmaceuticals Gmbh Carbonic anhydrase ix ligands
WO2024052431A1 (en) 2022-09-07 2024-03-14 3B Pharmaceuticals Gmbh Prostate specific membrane antigen (psma) ligands and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4637988A (en) * 1981-07-01 1987-01-20 Eastman Kodak Company Fluorescent labels for immunoassay
US4794191A (en) * 1981-07-01 1988-12-27 Eastman Kodak Company Fluorescent chelates
US4670572A (en) * 1981-07-01 1987-06-02 Eastman Kodak Company Phenolic fluorescent labels
US4801722A (en) * 1981-07-01 1989-01-31 Eastman Kodak Company Coumarin chelates
US4859777A (en) * 1981-07-01 1989-08-22 Eastman Kodak Company Terpyridine chelating agents
US4837169A (en) * 1981-07-01 1989-06-06 Eastman Kodak Company Polypyridine Fluorescent labels for immunoassay
US4767611A (en) * 1984-07-03 1988-08-30 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
DE3580420D1 (de) * 1984-08-13 1990-12-13 Hsc Res Dev Corp 1,10-phenanthrolin-2,9-dicarbonsaeure-derivate und deren verwendung fuer fluoreszens-immunoassay.
US5075447A (en) * 1984-09-17 1991-12-24 Hoffmann-La Roche Inc. Ruthenium complexes useful as carriers for immunologically active materials
DK365785A (da) * 1984-09-17 1986-03-18 Hoffmann La Roche Metalcomplexer
US4761481A (en) * 1985-03-18 1988-08-02 Baxter Travenol Laboratories, Inc. Substituted pyridine derivatives
SE8502573D0 (sv) * 1985-05-23 1985-05-23 Jouko Kanakre Fluorescent lanthanide chelates useful as labels of physiologically active materials
EP0272320B1 (en) * 1986-06-17 1994-03-23 Baxter Diagnostics Inc. Homogeneous fluoroassay methods employing fluorescent background rejection
AU8152887A (en) * 1986-10-17 1988-05-06 Cytogen Corporation Method for preparation of protein-chelator-metal ion compositions suitable for injection
SE8702824L (sv) * 1987-07-10 1989-01-11 Wallac Oy Metall-kelaterande 2,6-disubstituerade pyridinfoereningar och deras anvaendning
US5032677A (en) * 1987-11-06 1991-07-16 Baxter International Inc. Fluorescent poly(arylpyridine) rare earth chelates
JPH082878B2 (ja) * 1988-02-12 1996-01-17 富士写真フイルム株式会社 ４’−アルコキシ−２，２’：６’，２〃−デルピリジン誘導体及びその金属錯体
SE8800613D0 (sv) * 1988-02-23 1988-02-23 Wallac Oy A novel spectrofluorometric method and compounds that are of value for the method
US5202423A (en) * 1988-07-08 1993-04-13 Wallac Oy Terpyridine derivatives
SE8802575D0 (sv) * 1988-07-08 1988-07-08 Wallac Oy Terpyridine derivatives
FR2644785B1 (fr) * 1989-03-24 1991-07-05 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes metalliques formes par ces ligands et composition de diagnostic les contenant
GB8927503D0 (en) * 1989-12-04 1990-02-07 Kronem Systems Inc Enzyme-amplified lanthanide chelate luminescence
GB9001245D0 (en) * 1990-01-19 1990-03-21 Salutar Inc Compounds
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods

Also Published As

Publication number Publication date
DE69129127T2 (de) 1998-10-08
DE69129127D1 (de) 1998-04-23
NZ240521A (en) 1995-01-27
WO1992008494A3 (en) 1993-07-08
KR930701974A (ko) 1993-09-08
AU5583596A (en) 1996-08-01
ATE164082T1 (de) 1998-04-15
PT99460B (pt) 1999-02-26
US5707603A (en) 1998-01-13
US5523402A (en) 1996-06-04
MX9101999A (es) 1992-06-01
NO931631L (no) 1993-06-23
TW201271B (no) 1993-03-01
FI932083A (fi) 1993-07-02
EP0624097A1 (en) 1994-11-17
DK0624097T3 (da) 1998-10-19
WO1992008494A2 (en) 1992-05-29
AU9029191A (en) 1992-06-11
ES2113892T3 (es) 1998-05-16
HUT67298A (en) 1995-03-28
JPH06501703A (ja) 1994-02-24
CA2095123A1 (en) 1992-05-09
GR3026713T3 (en) 1998-07-31
JP3292301B2 (ja) 2002-06-17
FI932083A0 (fi) 1993-05-07
BR9107074A (pt) 1993-09-21
HU9301328D0 (en) 1993-10-28
IE913907A1 (en) 1992-05-20
AU667030B2 (en) 1996-03-07
PT99460A (pt) 1992-09-30
US5677445A (en) 1997-10-14
EP0624097B1 (en) 1998-03-18
US5367080A (en) 1994-11-22

Similar Documents

Publication Publication Date Title
NO931631D0 (no) Kompleksdannende midler og maalsoeking av radioaktive immunoreagenser nyttige innen terapeutiske og diagnostiske bildedannende sammensetninger og fremgangsmetoder
NO934425D0 (no) Preparater for nanopartikkelformige roentgenkontrastmidler
DE69117854D1 (de) Bilderzeugungsgerät
DE69120029D1 (de) Bilderzeugungsgerät
DE69122431D1 (de) Bilderzeugungsgerät
DE69115784D1 (de) Bilderzeugungsgerät
DE69121972T2 (de) Röntgenstrahlenmikroskop
DE69117865T2 (de) Bilderzeugungsgerät
NO982233D0 (no) Diagnostisk avbildningsmiddel
FI951872A (fi) Röntgenkuvauslaite
DE69130272T2 (de) Bilderzeugungsgerät
DE69133197D1 (de) Festkörper-Bildaufnahmevorrichtung
ITMI920540A0 (it) Apparecchio per lo sviluppo automatico di pellicole radiografiche in particolare in campo odontoiatrico
NO306467B1 (no) Joderte bor-forbindelser som er anvendelige som röntgenkontrastmidler, og farmasöytiske preparater inneholder disse
ATE134988T1 (de) Neue vorangeordnete sechszähnige liganden verwendbar in röntgenologischen bildformenden wirkstoffen
DE69418406T2 (de) Röntgenbildverstärker
KR950702196A (ko) 방사선 사진의 조영제에 유용한 6가 리간드(hexadentate ligands useful in radiogrphic imaging agents)
ITTO941014A0 (it) Dispositivo di irraggiamento per litografia rontgen di profondita'
IT219730Z2 (it) Dispositivo per il contenimento e l'esposizione di oggetti bidimensionali.
IL99982A0 (en) Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions
DE69530841D1 (de) Radioaktivmarkierte annexin-galaktose konjugate
EP0690727A4 (en) HEXADENT LIGANDS USEFUL IN RADIOGRAPHIC IMAGING AGENTS
ZA928304B (en) Contrast agents and compositions for radiological imaging and radiological imaging method utilizing same
IT9021921A0 (it) Dispositivo di realizzazione di multipli fotografici nonche' procedimento di realizzazione di multipli fotografici
NO962831D0 (no) Kontrastmidler for röntgen og magnettomografisk avbildning